Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Mismatch repair-deficient ...
AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...
Morning Overview on MSN
An mRNA vaccine halved the odds of aggressive melanoma returning after surgery
People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...
Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved ...
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study PD-1 immune checkpoint ...
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda ...
Please provide your email address to receive an email when new articles are posted on . Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results